TABLE 3.

Demographics, Disease Phenotype/Severity, and Length of Treatment in Subjects with ATI ≥5 or ATI <5 (n = 134)

Characteristic	ATI (U/mL)		P
	<5 (n = 107)	≥5 (n = 27)
Most recent diagnosis
CD	91 (85%)	23 (85%)	1.00
UC	16 (15%)	4 (15%)
Most recent disease severity
CD (PCDAI)	5.0 (0.0–10.0)	0.0 (0.0–10.0)	0.57
UC (PUCAI)	10.0 (0.0–15.0)	2.5 (0.0–15.0)	0.53
Disease remission
CD (PCDAI 0–10)	76 (84%)	19 (83%)	1.00
UC (PUCAI 0–9)	7 (44%)	3 (75%)	0.58
Months on infliximab	27.6 (14.2–57.2)a	19.2 (8.4–30.3)	0.01
Combination therapy	42 (39%)	8 (30%)	0.36
CRP obtained	105 (98%)	27 (100%)	1.00
CRP	0.10 (0.10–0.23)	0.11 (0.10–0.46)	0.34
CRP >0.5	11 (10%)	5 (19%)	0.32

^aBefore discontinuation.